&lt;p&gt;Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence&lt;/p&gt;

Napolitano, Maddalena; Fabbrocini, Gabriella; Cinelli, Eleonora; Stingeni, Luca; Patruno, Cataldo

doi:10.2147/jaa.s206387

Cited by 20 publications

(27 citation statements)

References 31 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As new agents come to market, the tradeoff between efficacy and safety will be important. While the JAK inhibitors are effective in clinical trials and offer a much desired oral form of delivery, they are associated with a risk of serious adverse effects [47,48]. There is an FDA mandated black box warning for risk of severe infection and death when using baricitinib 2 mg in patients with rheumatoid arthritis [48].…”

Section: Resultsmentioning

confidence: 99%

“…While the JAK inhibitors are effective in clinical trials and offer a much desired oral form of delivery, they are associated with a risk of serious adverse effects [47,48]. There is an FDA mandated black box warning for risk of severe infection and death when using baricitinib 2 mg in patients with rheumatoid arthritis [48]. This potential for serious adverse events is not surprising, as JAK inhibitors participate in signaling cascades that regulate both the acute inflammatory reaction and hematopoiesis [49,50].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

New and Emerging Systemic Treatments for Atopic Dermatitis

Newsom

Bashyam

Balogh

et al. 2020

Drugs

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a prevalent inflammatory skin condition that, depending on its severity, can cause enormous morbidity. Corticosteroids and systemic immunosuppression, traditionally standard of care for difficult-to-treat disease, have many undesirable side effects. The desire for targeted treatments along with an improved understanding of the pathophysiology of AD has spurred the development of novel treatments. In this article, we review promising new treatments and discuss how their targets-IL-13, IL-31, OX40 (CD134), and the Janus kinase family of proteins-participate in the pathogenesis of AD. We review the published phase II and III data for dupilumab, tralokinumab, lebrikizumab, nemolizumab, anti-OX40 antibody, baricitinib, abrocitinib, and upadacitinib. The introduction of new agents may offer new options, but it remains to be seen how narrow-acting agents, like single interleukin inhibitors, will compare in safety and efficacy to broad-acting agents such as JAK inhibitors. Key Points Our better understanding of the pathophysiology of AD has resulted in an explosion of research into new immunotherapies for this patient population. Multiple new agents targeting IL-13, IL-31, OX40 (CD134), and Janus kinase proteins may be effective for AD.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

New and Emerging Systemic Treatments for Atopic Dermatitis

Newsom

Bashyam

Balogh

et al. 2020

Drugs

View full text Add to dashboard Cite

show abstract

“…There were neither thromboembolic events nor considerable haematological changes in baricitinib groups 41 . At the moment, there are other ongoing clinical trials about the efficacy of baricitinib in managing moderate to severe AD of children and adolescents (e.g.NCT02576938; NCT03952559; NCT0343508; NCT03334435; NCT03428100) which their results would provide further evidence for including or excluding baricitinib in the approved medications of atopic dermatitis 42 .…”

Section: Atopic Dermatitismentioning

confidence: 99%

Baricitinib: From Rheumatoid Arthritis to COVID‐19

Assadiasl

Fatahi

Mosharmovahed

et al. 2021

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Baricitinib is a JAK1/2 inhibitor first approved for treating moderate to severe rheumatoid arthritis but later showed considerable efficacy in the control of exaggerated inflammatory responses that occur in a wide range of diseases. There is a growing body of evidence, obtained from clinical trials and case reports, demonstrating clinical and paraclinical improvement in patients following administration of baricitinib including rheumatoid arthritis, systemic lupus erythematosus, psoriasis, atopic dermatitis, alopecia areata, interferon-mediated auto-inflammatory diseases, graft versus host disease, diabetic kidney disease, and recently, coronavirus disease-19. However, despite overall encouraging results, many adverse effects have been observed in baricitinib-treated patients ranging from simple infections to increased risk of malignancies, particularly in long-term use. The significant efficacy of baricitinib on one hand and the probable adverse effects, on the other hand, urge for further investigations before establishing it as a part of standard therapeutic protocols.Herein, we have provided a review of the studies which have used baricitinib for treating various inflammatory disorders and summarized the advantages and disadvantages of its administration.

show abstract

“…Baricitinib is one of the oral first‐generation JAK inhibitors that are selective for JAK1 and JAK2 36,38,42 . Baricitinib is excreted through renal (~75% of the dose administrated) and gastrointestinal (~20%) elimination 43 . Two phase III studies on baricitinib as monotherapy for moderate to severe AD were performed to evaluate its efficacy and safety: BREEZE‐AD1 and BREEZE‐AD2 39 .…”

Section: Jakmentioning

confidence: 99%

Emerging treatments for atopic dermatitis

Katoh

2020

The Journal of Dermatology

View full text Add to dashboard Cite

Increasing information on the pathophysiology of atopic dermatitis (AD), accumulating data on cellular and molecular pathways in immunological reactions and inflammation, and the expansion of biotechnology and pharmacology have collectively contributed to the development of new pharmacological agents for AD. Novel pharmaceutical agents, including biologics targeting cytokines, which play pathogenetic roles in AD, for example, interleukin (IL)‐4, IL‐13, IL‐31 and IL‐22, Janus kinase inhibitors, phosphodiesterase 4 inhibitors and histamine H4 receptor antagonists, have been approved or are being developed. These agents are expected to be effective in AD patients with skin signs and/or symptoms that are refractory to conventional treatments. The development of novel drugs will accompany the use of predictive biomarkers for each agent in order to optimize treatment in each patient. Convenient tools that support self‐decision‐making by patients to reflect their preferences, which will increase treatment satisfaction and adherence, are also anticipated.

show abstract

<p>Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence</p>

Cited by 20 publications

References 31 publications

New and Emerging Systemic Treatments for Atopic Dermatitis

New and Emerging Systemic Treatments for Atopic Dermatitis

Baricitinib: From Rheumatoid Arthritis to COVID‐19

Emerging treatments for atopic dermatitis

Contact Info

Product

Resources

About